Gestational Diabetes Treatment Market - Global Outlook and Forecast 2021-2027

March 2021 | 109 pages | ID: G9D0884C24E7EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Gestational Diabetes Treatment in Global, including the following market information:

Global Gestational Diabetes Treatment Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Gestational Diabetes Treatment market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gestational Diabetes Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gestational Diabetes Treatment Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Gestational Diabetes Treatment Market Segment Percentages, By Type, 2020 (%)

• Insulin
• SGLT-2 Inhibitors
• Alpha-glucosidase Inhibitors
• Others

China Gestational Diabetes Treatment Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Gestational Diabetes Treatment Market Segment Percentages, By Application, 2020 (%)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gestational Diabetes Treatment Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Gestational Diabetes Treatment Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Gestational Diabetes Treatment Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Gestational Diabetes Treatment Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Biocon Limited
• Eli Lilly
• Novo Nordisk
• Boehringer Ingelheim GmbH
• Sanofi S.A.
• Sun Pharmaceutical Industries Limited
• Merck
• Novartis
• Adocia
• Peptron
• AstraZeneca plc
• Pfizer, Inc
• Takeda Pharmaceutical Company Ltd
• Abbott
• Antares Pharma
• INJEX Pharma AG
• Daiichi Sankyo

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Gestational Diabetes Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Gestational Diabetes Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL GESTATIONAL DIABETES TREATMENT OVERALL MARKET SIZE

2.1 Global Gestational Diabetes Treatment Market Size: 2021 VS 2027
2.2 Global Gestational Diabetes Treatment Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Gestational Diabetes Treatment Players in Global Market
3.2 Top Global Gestational Diabetes Treatment Companies Ranked by Revenue
3.3 Global Gestational Diabetes Treatment Revenue by Companies
3.4 Top 3 and Top 5 Gestational Diabetes Treatment Companies in Global Market, by Revenue in 2020
3.5 Global Companies Gestational Diabetes Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gestational Diabetes Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Gestational Diabetes Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Gestational Diabetes Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Gestational Diabetes Treatment Market Size Markets, 2021 & 2027
  4.1.2 Insulin
  4.1.3 SGLT-2 Inhibitors
  4.1.4 Alpha-glucosidase Inhibitors
  4.1.5 Others
4.2 By Type - Global Gestational Diabetes Treatment Revenue & Forecasts
  4.2.1 By Type - Global Gestational Diabetes Treatment Revenue, 2016-2021
  4.2.2 By Type - Global Gestational Diabetes Treatment Revenue, 2022-2027
  4.2.3 By Type - Global Gestational Diabetes Treatment Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Gestational Diabetes Treatment Market Size, 2021 & 2027
  5.1.2 Hospital Pharmacies
  5.1.3 Retail Pharmacies
  5.1.4 Online Pharmacies
5.2 By Application - Global Gestational Diabetes Treatment Revenue & Forecasts
  5.2.1 By Application - Global Gestational Diabetes Treatment Revenue, 2016-2021
  5.2.2 By Application - Global Gestational Diabetes Treatment Revenue, 2022-2027
  5.2.3 By Application - Global Gestational Diabetes Treatment Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Gestational Diabetes Treatment Market Size, 2021 & 2027
6.2 By Region - Global Gestational Diabetes Treatment Revenue & Forecasts
  6.2.1 By Region - Global Gestational Diabetes Treatment Revenue, 2016-2021
  6.2.2 By Region - Global Gestational Diabetes Treatment Revenue, 2022-2027
  6.2.3 By Region - Global Gestational Diabetes Treatment Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Gestational Diabetes Treatment Revenue, 2016-2027
  6.3.2 US Gestational Diabetes Treatment Market Size, 2016-2027
  6.3.3 Canada Gestational Diabetes Treatment Market Size, 2016-2027
  6.3.4 Mexico Gestational Diabetes Treatment Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Gestational Diabetes Treatment Revenue, 2016-2027
  6.4.2 Germany Gestational Diabetes Treatment Market Size, 2016-2027
  6.4.3 France Gestational Diabetes Treatment Market Size, 2016-2027
  6.4.4 U.K. Gestational Diabetes Treatment Market Size, 2016-2027
  6.4.5 Italy Gestational Diabetes Treatment Market Size, 2016-2027
  6.4.6 Russia Gestational Diabetes Treatment Market Size, 2016-2027
  6.4.7 Nordic Countries Gestational Diabetes Treatment Market Size, 2016-2027
  6.4.8 Benelux Gestational Diabetes Treatment Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Gestational Diabetes Treatment Revenue, 2016-2027
  6.5.2 China Gestational Diabetes Treatment Market Size, 2016-2027
  6.5.3 Japan Gestational Diabetes Treatment Market Size, 2016-2027
  6.5.4 South Korea Gestational Diabetes Treatment Market Size, 2016-2027
  6.5.5 Southeast Asia Gestational Diabetes Treatment Market Size, 2016-2027
  6.5.6 India Gestational Diabetes Treatment Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Gestational Diabetes Treatment Revenue, 2016-2027
  6.6.2 Brazil Gestational Diabetes Treatment Market Size, 2016-2027
  6.6.3 Argentina Gestational Diabetes Treatment Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Gestational Diabetes Treatment Revenue, 2016-2027
  6.7.2 Turkey Gestational Diabetes Treatment Market Size, 2016-2027
  6.7.3 Israel Gestational Diabetes Treatment Market Size, 2016-2027
  6.7.4 Saudi Arabia Gestational Diabetes Treatment Market Size, 2016-2027
  6.7.5 UAE Gestational Diabetes Treatment Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Biocon Limited
  7.1.1 Biocon Limited Corporate Summary
  7.1.2 Biocon Limited Business Overview
  7.1.3 Biocon Limited Gestational Diabetes Treatment Major Product Offerings
  7.1.4 Biocon Limited Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.1.5 Biocon Limited Key News
7.2 Eli Lilly
  7.2.1 Eli Lilly Corporate Summary
  7.2.2 Eli Lilly Business Overview
  7.2.3 Eli Lilly Gestational Diabetes Treatment Major Product Offerings
  7.2.4 Eli Lilly Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.2.5 Eli Lilly Key News
7.3 Novo Nordisk
  7.3.1 Novo Nordisk Corporate Summary
  7.3.2 Novo Nordisk Business Overview
  7.3.3 Novo Nordisk Gestational Diabetes Treatment Major Product Offerings
  7.3.4 Novo Nordisk Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.3.5 Novo Nordisk Key News
7.4 Boehringer Ingelheim GmbH
  7.4.1 Boehringer Ingelheim GmbH Corporate Summary
  7.4.2 Boehringer Ingelheim GmbH Business Overview
  7.4.3 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Major Product Offerings
  7.4.4 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.4.5 Boehringer Ingelheim GmbH Key News
7.5 Sanofi S.A.
  7.5.1 Sanofi S.A. Corporate Summary
  7.5.2 Sanofi S.A. Business Overview
  7.5.3 Sanofi S.A. Gestational Diabetes Treatment Major Product Offerings
  7.5.4 Sanofi S.A. Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.5.5 Sanofi S.A. Key News
7.6 Sun Pharmaceutical Industries Limited
  7.6.1 Sun Pharmaceutical Industries Limited Corporate Summary
  7.6.2 Sun Pharmaceutical Industries Limited Business Overview
  7.6.3 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Major Product Offerings
  7.6.4 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.6.5 Sun Pharmaceutical Industries Limited Key News
7.7 Merck
  7.7.1 Merck Corporate Summary
  7.7.2 Merck Business Overview
  7.7.3 Merck Gestational Diabetes Treatment Major Product Offerings
  7.4.4 Merck Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.7.5 Merck Key News
7.8 Novartis
  7.8.1 Novartis Corporate Summary
  7.8.2 Novartis Business Overview
  7.8.3 Novartis Gestational Diabetes Treatment Major Product Offerings
  7.8.4 Novartis Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.8.5 Novartis Key News
7.9 Adocia
  7.9.1 Adocia Corporate Summary
  7.9.2 Adocia Business Overview
  7.9.3 Adocia Gestational Diabetes Treatment Major Product Offerings
  7.9.4 Adocia Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.9.5 Adocia Key News
7.10 Peptron
  7.10.1 Peptron Corporate Summary
  7.10.2 Peptron Business Overview
  7.10.3 Peptron Gestational Diabetes Treatment Major Product Offerings
  7.10.4 Peptron Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.10.5 Peptron Key News
7.11 AstraZeneca plc
  7.11.1 AstraZeneca plc Corporate Summary
  7.11.2 AstraZeneca plc Business Overview
  7.11.3 AstraZeneca plc Gestational Diabetes Treatment Major Product Offerings
  7.11.4 AstraZeneca plc Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.11.5 AstraZeneca plc Key News
7.12 Pfizer, Inc
  7.12.1 Pfizer, Inc Corporate Summary
  7.12.2 Pfizer, Inc Business Overview
  7.12.3 Pfizer, Inc Gestational Diabetes Treatment Major Product Offerings
  7.12.4 Pfizer, Inc Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.12.5 Pfizer, Inc Key News
7.13 Takeda Pharmaceutical Company Ltd
  7.13.1 Takeda Pharmaceutical Company Ltd Corporate Summary
  7.13.2 Takeda Pharmaceutical Company Ltd Business Overview
  7.13.3 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Major Product Offerings
  7.13.4 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.13.5 Takeda Pharmaceutical Company Ltd Key News
7.14 Abbott
  7.14.1 Abbott Corporate Summary
  7.14.2 Abbott Business Overview
  7.14.3 Abbott Gestational Diabetes Treatment Major Product Offerings
  7.14.4 Abbott Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.14.5 Abbott Key News
7.15 Antares Pharma
  7.15.1 Antares Pharma Corporate Summary
  7.15.2 Antares Pharma Business Overview
  7.15.3 Antares Pharma Gestational Diabetes Treatment Major Product Offerings
  7.15.4 Antares Pharma Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.15.5 Antares Pharma Key News
7.16 INJEX Pharma AG
  7.16.1 INJEX Pharma AG Corporate Summary
  7.16.2 INJEX Pharma AG Business Overview
  7.16.3 INJEX Pharma AG Gestational Diabetes Treatment Major Product Offerings
  7.16.4 INJEX Pharma AG Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.16.5 INJEX Pharma AG Key News
7.17 Daiichi Sankyo
  7.17.1 Daiichi Sankyo Corporate Summary
  7.17.2 Daiichi Sankyo Business Overview
  7.17.3 Daiichi Sankyo Gestational Diabetes Treatment Major Product Offerings
  7.17.4 Daiichi Sankyo Gestational Diabetes Treatment Revenue in Global (2016-2021)
  7.17.5 Daiichi Sankyo Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Gestational Diabetes Treatment Market Opportunities & Trends in Global Market
Table 2. Gestational Diabetes Treatment Market Drivers in Global Market
Table 3. Gestational Diabetes Treatment Market Restraints in Global Market
Table 4. Key Players of Gestational Diabetes Treatment in Global Market
Table 5. Top Gestational Diabetes Treatment Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Gestational Diabetes Treatment Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Gestational Diabetes Treatment Revenue Share by Companies, 2016-2021
Table 8. Global Companies Gestational Diabetes Treatment Product Type
Table 9. List of Global Tier 1 Gestational Diabetes Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gestational Diabetes Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Gestational Diabetes Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Gestational Diabetes Treatment Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Gestational Diabetes Treatment Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Gestational Diabetes Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Gestational Diabetes Treatment Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Gestational Diabetes Treatment Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Gestational Diabetes Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Gestational Diabetes Treatment Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Gestational Diabetes Treatment Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Gestational Diabetes Treatment Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Gestational Diabetes Treatment Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Gestational Diabetes Treatment Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Gestational Diabetes Treatment Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Gestational Diabetes Treatment Revenue, (US$, Mn), 2022-2027
Table 30. Biocon Limited Corporate Summary
Table 31. Biocon Limited Gestational Diabetes Treatment Product Offerings
Table 32. Biocon Limited Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 33. Eli Lilly Corporate Summary
Table 34. Eli Lilly Gestational Diabetes Treatment Product Offerings
Table 35. Eli Lilly Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 36. Novo Nordisk Corporate Summary
Table 37. Novo Nordisk Gestational Diabetes Treatment Product Offerings
Table 38. Novo Nordisk Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 39. Boehringer Ingelheim GmbH Corporate Summary
Table 40. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Product Offerings
Table 41. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 42. Sanofi S.A. Corporate Summary
Table 43. Sanofi S.A. Gestational Diabetes Treatment Product Offerings
Table 44. Sanofi S.A. Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 45. Sun Pharmaceutical Industries Limited Corporate Summary
Table 46. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Product Offerings
Table 47. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 48. Merck Corporate Summary
Table 49. Merck Gestational Diabetes Treatment Product Offerings
Table 50. Merck Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 51. Novartis Corporate Summary
Table 52. Novartis Gestational Diabetes Treatment Product Offerings
Table 53. Novartis Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 54. Adocia Corporate Summary
Table 55. Adocia Gestational Diabetes Treatment Product Offerings
Table 56. Adocia Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 57. Peptron Corporate Summary
Table 58. Peptron Gestational Diabetes Treatment Product Offerings
Table 59. Peptron Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 60. AstraZeneca plc Corporate Summary
Table 61. AstraZeneca plc Gestational Diabetes Treatment Product Offerings
Table 62. AstraZeneca plc Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 63. Pfizer, Inc Corporate Summary
Table 64. Pfizer, Inc Gestational Diabetes Treatment Product Offerings
Table 65. Pfizer, Inc Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 66. Takeda Pharmaceutical Company Ltd Corporate Summary
Table 67. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Product Offerings
Table 68. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 69. Abbott Corporate Summary
Table 70. Abbott Gestational Diabetes Treatment Product Offerings
Table 71. Abbott Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 72. Antares Pharma Corporate Summary
Table 73. Antares Pharma Gestational Diabetes Treatment Product Offerings
Table 74. Antares Pharma Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 75. INJEX Pharma AG Corporate Summary
Table 76. INJEX Pharma AG Gestational Diabetes Treatment Product Offerings
Table 77. INJEX Pharma AG Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)
Table 78. Daiichi Sankyo Corporate Summary
Table 79. Daiichi Sankyo Gestational Diabetes Treatment Product Offerings
Table 80. Daiichi Sankyo Gestational Diabetes Treatment Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Gestational Diabetes Treatment Segment by Type
Figure 2. Gestational Diabetes Treatment Segment by Application
Figure 3. Global Gestational Diabetes Treatment Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Gestational Diabetes Treatment Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Gestational Diabetes Treatment Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gestational Diabetes Treatment Revenue in 2020
Figure 8. By Type - Global Gestational Diabetes Treatment Revenue Market Share, 2016-2027
Figure 9. By Application - Global Gestational Diabetes Treatment Revenue Market Share, 2016-2027
Figure 10. By Region - Global Gestational Diabetes Treatment Revenue Market Share, 2016-2027
Figure 11. By Country - North America Gestational Diabetes Treatment Revenue Market Share, 2016-2027
Figure 12. US Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Gestational Diabetes Treatment Revenue Market Share, 2016-2027
Figure 16. Germany Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 17. France Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Gestational Diabetes Treatment Revenue Market Share, 2016-2027
Figure 24. China Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 28. India Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Gestational Diabetes Treatment Revenue Market Share, 2016-2027
Figure 30. Brazil Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Gestational Diabetes Treatment Revenue Market Share, 2016-2027
Figure 33. Turkey Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Gestational Diabetes Treatment Revenue, (US$, Mn), 2016-2027
Figure 37. Biocon Limited Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Eli Lilly Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Novo Nordisk Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Sanofi S.A. Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Merck Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Novartis Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Adocia Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Peptron Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. AstraZeneca plc Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Pfizer, Inc Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 49. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 50. Abbott Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 51. Antares Pharma Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 52. INJEX Pharma AG Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 53. Daiichi Sankyo Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)